Artikel
Effects of guideline adherent adjuvant treatment in primary breast cancer – A retrospective multi-center-cohort study of 3,976 patients
Suche in Medline nach
Autoren
Veröffentlicht: | 10. Juli 2012 |
---|
Gliederung
Text
Background: The aim of that study was to analyze the impact of guideline adherent adjuvant treatment in early breast cancer on survival in a non-selected retrospective clinical cohort.
Methods: A retrospective multi-center cohort study called BRENDA (‘breast cancer under evidence based guidelines’) analyzed 3976 patients first diagnosed with primary breast. The classification of guideline adherent adjuvant treatment was based on the German national S3-guideline for diagnosis and treatment of breast cancer.
Results: There was a significant association between treatment adherence and prolonged recurrence free [p<0.001; HR=2.20 (95% CI: 1.74–2.79)] and overall survival [p<0.001; HR=2.57 (95% CI: 1.96–3.37)]. The greater the number of violations in guideline adherence, the lower was overall survival (p<0.0001). Advanced age at initial diagnosis was additionally associated with a reduction in guideline adherence. The percentage of guideline adherence for the therapeutic modalities BCT, mastectomy, axillary dissection and hormone therapy was greater than 80%. For chemotherapy, the percent of guideline adherence was 71.4%.
Conclusion: There is a strong association between guideline adherent adjuvant treatment and improved survival in primary breast cancer.